Orally administered recombinant Lactobacillus expressing African swine fever virus antigens that induced immunity responses

African swine fever (ASF) is a highly contagious, acute, febrile disease caused by the African swine fever virus (ASFV), with morbidity and mortality rates approaching 100% in domestic and wild swine, resulting in massive economic losses to the pig industry worldwide. This study aimed to express the...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in microbiology 2023-01, Vol.13, p.1103327-1103327
Main Authors: Zhang, Hongliang, Zhao, Saisai, Zhang, Haojie, Shen, Yu, Zhang, Peijun, Shan, Hu, Cai, Xiulei
Format: Article
Language:English
Subjects:
African swine fever virus
enterotoxin B subunit
immunogenicity evaluation
Lactococcus lactis
Microbiology
oral immunization
recombinant expression
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:African swine fever (ASF) is a highly contagious, acute, febrile disease caused by the African swine fever virus (ASFV), with morbidity and mortality rates approaching 100% in domestic and wild swine, resulting in massive economic losses to the pig industry worldwide. This study aimed to express the p30, p54, and p72 proteins encoded by ASFV using the ( ) expression system. Here, six new functional recombinant were constructed, and the expression of the p30 protein, p54 protein, p72 protein, p30-LTB (heat-labile enterotoxin B, LTB) fusion protein, p54-LTB fusion protein, and the p72-LTB fusion protein was successfully detected by Western blot analysis. Following oral immunization of rabbits with recombinant , serum IgG, intestinal mucosal sIgA, cytokines (IL-4 and INF-γ), and splenocyte viability were higher than in the control group ELISA. Notably, without the LTB adjuvant group, humoral and Th1 cellular immunity were promoted, whereas, with the LTB adjuvant group, local mucosal immunity, humoral immunity, and Th2 cellular immunity were promoted, providing new insights into the design and development of an ASFV subunit vaccine.
ISSN:1664-302X
1664-302X
DOI:10.3389/fmicb.2022.1103327